Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Société Générale M&A Activity 2021

Jun 17, 2021

1671_mrq_2021-06-17_e4352c5d-ef0b-4239-addb-9e800a2bc84e.html

M&A Activity

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 2188C

Societe Generale SA

17 June 2021

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1) Société Générale S.A.
Company dealt in UDG Healthcare plc
Class of relevant security to which the dealings being disclosed relate (Note 2) €0.05 ordinary shares
Date of dealing 16/06/2021

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long Short
Number (%) Number (%)
(1) Relevant securities 10,295,744 4.09 4,867 0.00
(2) Derivatives (other than options) 0 0.00 6,233,855 2.47
(3) Options and agreements to purchase/sell 0 0.00 0 0.00
Total *10,355,744 *4.11 6,238,722 2.48

* Include the holding of 60,000 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale Number of relevant securities Price per unit GBP (Note 5)
Purchase 411 10.47
Purchase 250 10.46
Purchase 60 10.46
Purchase 411 10.46
Purchase 502 10.47
Purchase 250 10.47
Purchase 26 10.46
Purchase 243 10.47
Purchase 256 10.46
Purchase 30,000 10.440023
Purchase 15,000 10.440023
Sale 943 10.5
Sale 10,050 10.5
Sale 792 10.5
Sale 5,116 10.5
Sale 295 10.46
Sale 250 10.46
Sale 266 10.44
Sale 297 10.46
Sale 3 10.46
Sale 3 10.46
Sale 297 10.46
Sale 297 10.46
Sale 3 10.46
Sale 3 10.46
Sale 3 10.46
Sale 112 10.46
Sale 551 10.46
Sale 3 10.46
Sale 3 10.46
Sale 3 10.46
Sale 220 10.47
Sale 77 10.47
Sale 3 10.46
Sale 297 10.47
Sale 297 10.46
Sale 297 10.47
Sale 297 10.46
Sale 297 10.46
Sale 741 10.45
Sale 295 10.46
Sale 295 10.46
Sale 295 10.47
Sale 14 10.44
Sale 295 10.47
Sale 295 10.46
Sale 1 10.46
Sale 295 10.46
Sale 295 10.47
Sale 295 10.46
Sale 11 10.48
Sale 439 10.46
Sale 481 10.46
Sale 184 10.46
Sale 329 10.46
Sale 243 10.47
Sale 250 10.46
Sale 250 10.48
Sale 423 10.47
Sale 793 10.46
Sale 390 10.455
Sale 54 10.48
Sale 223 10.47
Sale 325 10.45
Sale 26 10.46
Sale 243 10.47
Sale 256 10.46
Total Purchases 47,409
Total Sales 29,111

Derivatives transactions (other than options transactions)

Product name,

e.g. CFD
Nature of transaction

(Note 6)
Number of relevant securities

(Note 7)
Price per unit GBP

(Note 5)
CFD Increased short 30,000 10.440023
CFD Increased short 15,000 10.440023

(b)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name,

e.g. call option
Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name,

e.g. call option
Number of securities Exercise price per unit (Note 5)

(c)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)
Details Price per unit

(if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements, or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the 

voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition 

or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            No

Date of disclosure 17/06/2021
Contact name Société Générale - Disclosure team
Telephone number +33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEEAKKXFELFEEA